Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cacabelos

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Journal of Neural Transmission. Supplementum|August 29, 2000
Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjectsX A Alvarez, V R Lombardi, L Corzo, et al.
Drugs of Today (Barcelona, Spain : 1998)|July 16, 2003
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomicsR Cacabelos, A Alvarez, V Lombardi, et al.
European Journal of Neurology|January 20, 2006
A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's diseaseX A Alvarez, R Cacabelos, M Laredo, et al.
Current Medicinal Chemistry|December 31, 2013
Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer diseaseG Aliev, M Priyadarshini, V P Reddy, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Journal of Neural Transmission. Supplementum|August 29, 2000
Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjectsX A Alvarez, V R Lombardi, L Corzo, et al.
Drugs of Today (Barcelona, Spain : 1998)|July 16, 2003
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomicsR Cacabelos, A Alvarez, V Lombardi, et al.
European Journal of Neurology|January 20, 2006
A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's diseaseX A Alvarez, R Cacabelos, M Laredo, et al.
Current Medicinal Chemistry|December 31, 2013
Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer diseaseG Aliev, M Priyadarshini, V P Reddy, et al.
Pageof 11